Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • china cas 2647-50-9 flubromazepam

Nov . 22, 2024 10:38 Back to list

china cas 2647-50-9 flubromazepam



Understanding Flubromazepam A Look at China CAS 2647-50-9


Flubromazepam, with the chemical identification CAS 2647-50-9, is a novel psychoactive substance that belongs to the benzodiazepine class of medications. This compound has gained attention in both scientific research and policymaking due to its psychoactive properties and potential implications for public health.


Chemical Structure and Properties


Flubromazepam is a derivative of the benzodiazepine family, which is known for its psychoactive effects, including anxiolytic (anxiety-reducing), sedative, muscle relaxant, and anticonvulsant properties. The chemical structure of flubromazepam includes a bromine atom, which distinguishes it from other benzodiazepines. This structural modification can influence its pharmacological profile, possibly affecting its potency, efficacy, and side effects. The molecular formula for flubromazepam is C15H13BrN2O, and its molecular weight is approximately 319.18 g/mol.


Mechanism of Action


Like other benzodiazepines, flubromazepam primarily exerts its effects by modulating the gamma-aminobutyric acid (GABA) neurotransmitter system in the brain. GABA is the main inhibitory neurotransmitter, and benzodiazepines enhance its effect on the GABA-A receptor, leading to increased neuronal inhibition. This results in various effects, such as sedation, muscle relaxation, and anxiolysis. The potency of flubromazepam can be attributed to its ability to bind effectively to the GABA-A receptors, although detailed studies on specific binding affinities and receptor subtype preferences are still ongoing.


Uses and Implications

Flubromazepam, like other benzodiazepines, was initially developed for therapeutic uses, including the treatment of anxiety disorders, insomnia, and seizures. However, it has become increasingly popular in non-medical contexts, leading to its emergence on the unregulated drug market. The recreational use of this substance has raised concerns among healthcare providers and regulatory agencies due to the risks associated with its use, such as overdose, dependence, and withdrawal symptoms.


china cas 2647-50-9 flubromazepam

china cas 2647-50-9 flubromazepam

Risks and Side Effects


The side effects associated with flubromazepam use can be significant, particularly in non-prescribed or high-dose scenarios. Common side effects include drowsiness, dizziness, confusion, and impaired coordination, which can pose risks for individuals who engage in activities that require mental alertness, such as driving. Long-term use can lead to physical dependence and tolerance, where higher doses are required to achieve the same effect. Withdrawal symptoms can be severe and may include anxiety, agitation, seizures, and insomnia.


Furthermore, the lack of regulation surrounding flubromazepam poses additional risks. Users may not be aware of the purity, potency, or composition of the substance they consume, leading to unpredictable effects and increased risk of overdose.


Legal Status and Regulation


The legal status of flubromazepam varies by country and region. In many places, it may fall under analogue laws or specific drug scheduling, which classify it as a controlled substance. Governments and regulatory bodies are continually adapting their laws in response to the rise of new psychoactive substances, including flubromazepam, to protect public health and safety.


Conclusion


Flubromazepam, represented by the CAS number 2647-50-9, exemplifies the ongoing challenges posed by novel psychoactive substances in contemporary society. While it possesses potential therapeutic benefits as part of the benzodiazepine class, its growing prevalence in recreational contexts highlights the need for increased awareness and regulation. Continued research and monitoring are crucial in addressing the implications of flubromazepam use, ensuring that individuals are informed about its risks, and developing appropriate measures to safeguard public health.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
en_USEnglish
afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona sdSindhi si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu en_USEnglish